Table 1.

Patient demographics at baseline (N = 321)

	Values
Median age, y (range)	58 (21-85)
Median duration of CML, mo (range)	58 (5-275)
Median duration of prior imatinib therapy, mo (range)	32 (< 1 to 94)
Imatinib resistant	39 (2-94)
Imatinib intolerant	14 (< 1 to 64)
Active disease before therapy, n (%)	207 (64)
Imatinib resistant/intolerant (%)	70/30
Prior imatinib ≥ 12 mo, n (%)	266 (83)
Imatinib resistant, n/N (%)	215/226 (95)
Imatinib intolerant, n/N (%)	51/94* (54)
Prior highest imatinib dose ≥ 600 mg/d, n (%)	232 (72)
Imatinib resistant, n/N (%)	201/226 (89)
Imatinib intolerant, n/N (%)	31/94 (33)
Other prior therapy
Hydroxyurea, n (%)	266 (83)
Interferon, n (%)	187 (58)
Cytarabine, n (%)	78 (24)
Response at baseline, n (%)
Complete hematologic response	114 (36)
Major cytogenetic response	35 (11)
Complete cytogenetic response	10 (3)

CML indicates chronic myeloid leukemia; active disease refers to patients not in complete hematologic response at the time of study entry.

^*Imatinib dosing information was missing for 1 patient.